Evaluation of tumour hypoxia during radiotherapy using \(^{18}\text{F}\)HX4 PET imaging and blood biomarkers in patients with head and neck cancer

Catharina M. L. Zegers\(^1\) · Frank J. P. Hoebers\(^1\) · Wouter van Elmp\(^1\) · Judith A. Bons\(^2\) · Michel C. Öllers\(^1\) · Esther G. C. Troost\(^{1,3,4}\) · Daniëlle Eekers\(^1\) · Leo Balmaekers\(^1\) · Marlies Arts-Pechtold\(^1\) · Felix M. Mottaghy\(^{5,6}\) · Philippe Lambin\(^1\)

Received: 18 March 2016 / Accepted: 19 May 2016 / Published online: 1 June 2016

Abstract

**Background and purpose** Increased tumour hypoxia is associated with a worse overall survival in patients with head and neck squamous cell carcinoma (HNSCC). The aims of this study were to evaluate treatment-associated changes in \(^{18}\text{F}\)HX4-PET, hypoxia-related blood biomarkers, and their interdependence.

**Material and methods** \(^{18}\text{F}\)HX4-PET/CT scans of 20 patients with HNSCC were acquired at baseline and after ±20Gy of radiotherapy. Within the gross-tumour-volumes (GTV; primary and lymph nodes), mean and maximum standardized uptake values, the hypoxic fraction (HF) and volume (HV) were calculated. Also, the changes in spatial uptake pattern were evaluated using \(^{18}\text{F}\)HX4-PET/CT imaging. For all patients, the plasma concentration of CAIX, osteopontin and VEGF was assessed.

**Results** At baseline, tumour hypoxia was detected in 69 % (22/32) of the GTVs. During therapy, we observed a significant decrease in all image parameters. The HF decreased from 21.7 ± 19.8 % (baseline) to 3.6 ± 10.0 % (during treatment; \(P < 0.001\)). Only two patients had a HV > 1 cm\(^3\) during treatment, which was located for >98 % within the baseline HV. During treatment, no significant changes in plasma CAIX or VEGF were observed, while osteopontin was increased.

**Conclusions** \(^{18}\text{F}\)HX4-PET/CT imaging allows monitoring changes in hypoxia during (chemo)radiotherapy whereas the blood biomarkers were not able to detect a treatment-associated decrease in hypoxia.

**Keywords** Hypoxia · PET · CAIX · Osteopontin · VEGF

**Introduction**

Tumour cell hypoxia is known to promote resistance to cancer treatment, to increase tumour aggressiveness, and to be a prognostic factor for survival [1]. Non-invasive imaging of tumour hypoxia by means of positron emission tomography (PET) has been shown to predict loco-regional control and survival, and may be used to select patients for additional anti-hypoxia therapy [2–4]. In addition, PET imaging can be used to monitor the response to treatment. Previous studies using the hypoxia PET tracer \(^{18}\text{F}\)FMISO and the metabolic PET tracer \(^{18}\text{F}\)FDG observed that the uptake changes (early) during (chemo)radiotherapy had a higher predictive value than pre-treatment measurements [3, 5]. Previously, Overgaard [6] showed that the modification of hypoxia during
radiotherapy results in better loco-regional control and survival in patients with a squamous cell carcinoma of the head and neck (HNSCC). However, stratifying patients undergoing ARCON (accelerated radiotherapy with carbogen and nicotinamide) based on their pre-therapeutic hypoxic status (pimonidazole staining) demonstrated that the benefit in loco-regional control was specifically observed for patients with initial tumour hypoxia before the start of treatment [7, 8]. The pimonidazole staining of a biopsy, however, can only provide information about local hypoxia before the start of treatment. Non-invasive hypoxia PET imaging, on the other hand, provides an opportunity to perform repeated tumour hypoxia measurements in 3-dimensions. Therefore, hypoxia PET measurements may be used to select patients likely to have a benefit from additional anti-hypoxia therapy.

One of the hypoxia PET tracers to visualize and quantify tumour hypoxia is the 2-nitroimidazole-[18F]fluoro-2-(4-(2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol, [18F]HX4. In previous pre-clinical studies [18F]HX4 was validated as a hypoxia tracer, and the repeatability of the tracer uptake was assessed [9, 10]. In addition, in patients with non-small cell lung cancer (NSCLC), [18F]HX4 showed promising results and was shown to provide additional value to the metabolic PET tracer [18F]FDG [11, 12]. In this paper, we will investigate the potential of this tracer to detect treatment-associated changes in hypoxic tumour status in patients with HNSCC.

Another method to obtain information on tumour hypoxia may be the measurement of hypoxia-related proteins or enzymes in plasma. Potential relevant hypoxia markers are plasma osteopontin, carbonic anhydrase IX (CAIX), and vascular endothelial growth factor (VEGF). Osteopontin is activated under hypoxic conditions and is inversely correlated with the PO2 value of the tumour [13]. In addition, plasma osteopontin is a significant predictor for the response to radiotherapy in patients with head and neck cancer [14]. CAIX expression is upregulated under the influence of tumour hypoxia. Also, in patients with NSCLC, a high level of plasma CAIX was associated with a shorter overall survival [15]. Last, hypoxia activates hypoxia inducible factor (HIF-1), which induces a high expression of VEGF, the primary cytokine related to angiogenesis. VEGF may, therefore, serve as an indirect marker of tumour hypoxia. These three markers might have the potential to stratify patients based on their hypoxic tumour status.

The aims of this study were to evaluate the changes in hypoxia during treatment in patients with HNSCC, the spatial stability of the uptake pattern, and the presence of plasma osteopontin, CAIX, and VEGF in relationship to hypoxia imaging.

### Materials and methods

#### Patients

Between January 2012 and October 2014, we included 20 patients in this imaging study. Patient, tumour, and treatment characteristics are shown in Table 1. The study was approved by the Ethical Review Committee of Maastricht University Medical Centre and registered on clinicaltrial.gov (NCT01347281). All patients provided written informed consent before study entry.

#### PET/CT imaging

[18F]HX4 was produced as described in previous publications [9, 16–18]. After intravenous administration of an average (±SD) dose of 378 ± 84 MBq [18F]HX4, PET/CT imaging was performed at 1.5, 3, and 4 h post-injection (p.i.) for 15, 15, and 20 min, respectively, for a single bed position centred around the primary tumour. After ten patients, an interim analysis showed highest contrast at the imaging time-point at 4 h p.i., and this was used from then onwards.

[18F]HX4 PET/CT scans were acquired before the start of external beam radiotherapy and during the radiation treatment; after an average (±SD) dose of 21 ± 2 Gy using a Biograph 40 PET/CT scanner (Siemens Healthcare, Erlangen, Germany). Scatter and attenuation corrections were applied, PET images were reconstructed using OSEM 2D (Ordered Subset Expectation Maximization, four iterations, eight subsets) and a Gaussian filter of 5 mm. Imaging was performed in radiotherapy position, with the patient positioned on a flat table top using an immobilization mask and a movable laser alignment system.

#### Image analysis

The gross tumour volume of the primary lesion (GTV\textsubscript{prim}) and involved lymph nodes (GTV\textsubscript{ln}), were delineated on the [18F]FDG PET/CT, used for radiotherapy planning purposes, by two experienced radiation oncologists in consensus. These contours were copied to the [18F]HX4 PET scan at baseline and during treatment by rigid registration. Maximum and mean standardized uptake values (SUV\textsubscript{max} and SUV\textsubscript{mean}), were determined within the GTVs. In addition, the maximum tumour-to-muscle ratio (TMR\textsubscript{max}), was calculated, defined as the SUV\textsubscript{max} in the tumour divided by the SUV\textsubscript{mean} in the trapezius muscles (Supplementary Fig. 1). The hypoxic fraction (HF) and hypoxic volume (HV) were defined as the fraction or volume of the GTV with a TMR larger than 1.4.

To evaluate the spatial location of the [18F]HX4 PET uptake at baseline and during treatment, the [18F]HX4 PET/CT acquired during radiotherapy was rigidly registered to the baseline [18F]HX4 PET/CT. The rigid transformation was...
determined by the registration of the CT scans; subsequently, the same transformation was applied to the PET scans and GTV to co-register the images. A visual and voxel-wise comparison of the $[{^{18}}F]$HX4 uptake before and during radiotherapy was performed to compare spatial uptake patterns for both GTV$_{prim}$ and GTV$_{ln}$.

### Blood biomarker analysis

For all patients, blood samples were collected before and during (chemo)radiotherapy on the day of the $[{^{18}}F]$HX4 PET/CT scan. All blood biomarkers were measured in EDTA plasma. Samples were analysed simultaneously in a certified laboratory, using commercially available kits. CAIX was measured by a sandwich-type immunoassay that uses a mouse monoclonal capture antibody (V10) and a biotinylated mouse monoclonal antibody (M75) as detector (Nuclea Diagnostic Laboratories LLC, Cambridge, MA). Osteopontin and VEGF were measured by an ELISA method. A monoclonal antibody specific for osteopontin/VEGF was pre-coated onto the microplate and an enzyme-lined polyclonal antibody specific for osteopontin /VEGF was used as detector (R&D Systems (Minneapolis, MN).

To compare the plasma hypoxia markers with the $[{^{18}}F]$HX4 uptake in the GTV$_{prim}$ and GTV$_{ln}$, we hypothesize that these markers reflect the uptake in all lesions within one patient. Therefore, the image parameters of multiple GTVs were combined, providing one SUV$_{max}$ and TMR$_{max}$ (the maximum of the present lesions). The hypoxic volumes were summed and for the SUV$_{mean}$ a weighted average was calculated using:

$$\text{weighted SUV}_{\text{mean}} = \frac{SUV_{\text{mean GTV}_{\text{prim}}} * \text{GTV}_{\text{prim}} + SUV_{\text{mean GTV}_{\text{ln}}} * \text{GTV}_{\text{ln}}}{\text{GTV}_{\text{prim}} + \text{GTV}_{\text{ln}}}$$

### Statistical analysis

For all parameters, mean ± 1 standard deviation (SD) are reported. Non-parametric tests were used to determine significant differences in image and blood plasma parameters (Wilcoxon signed rank test) and to evaluate correlations between imaging parameters and blood parameters (Spearman’s correlation coefficient; $R_s$). Linear regressions were performed to quantify the voxel-wise comparison, and a Pearson correlation coefficient ($R_p$) was calculated. A $p$-value $<0.05$ was assumed to be statistically significant.

### Results

In this study we analysed the $[{^{18}}F]$HX4 uptake of 20 patients with HNSCC before the start of radiotherapy. For 3/20 patients the $[{^{18}}F]$HX4 PET scan during radiotherapy was not performed due to the patient’s preference or health status. Eleven patients had involvement of the lymph nodes (GTV$_{ln}$), which were separately analysed from the primary lesion (GTV$_{prim}$). The average lesion sizes for GTV$_{prim}$ was
17.6 ± 12.3 cm³ (range: 2.4–46.6 cm³) and for GTVln 22.6 ± 30.5 (range: 1.3–105.2 cm³).

[18F]HX4 PET uptake at baseline

In the first ten patients, [18F]HX4 PET/CT imaging was acquired at 1.5, 3, and 4 h p.i. In their lesions (10 GTVprim and 9 GTVln) we observed a significant increase in the TMRmax from 1.5 h (1.5 ± 0.3) to 3 h p.i. (1.7 ± 0.4; P < 0.01), and from 3 to 4 h p.i. (1.8 ± 0.6; P = 0.02) (Fig. 1). Therefore, [18F]HX4 PET/CT imaging at 4 h p.i. was selected as the standard and applied as the single imaging timepoint for the remaining patients.

At baseline we observed tumour hypoxia (TMR > 1.4 at 4 h p.i.) in 69% (22/32) of the GTVprim and GTVln. For all lesions, we observed an average SUVmean, SUVmax and TMRmax of 0.8 ± 0.2, 1.3 ± 0.5 and 1.7 ± 0.5, respectively. The average HF and HV were 16 ± 20% and 4.9 ± 9.6 cm³. All these image parameters were significantly correlated to the volume of the lesion, SUVmean (Rs = 0.38, p = 0.03), SUVmax (Rs = 0.57, p < 0.001), TMRmax (Rs = 0.75, p < 0.001), HF (Rs = 0.63, p < 0.001) and HV (Rs = 0.74, p < 0.001).

[18F]HX4 PET uptake during treatment

We observed a significant correlation between the image parameters measured at baseline and during treatment: SUVmean (Rs = 0.66, P < 0.001), SUVmax (Rs = 0.63, P < 0.001), TBRmax (Rs = 0.57, P < 0.01), HF (Rs = 0.56, P < 0.01), HV (Rs = 0.52, P < 0.01). Taking into account the hypoxic lesions (GTVprim and GTVln), with a [18F]HX4 PET/CT scan at baseline and during treatment (N = 17), we observed a significant decrease in all image-derived parameters during therapy (Table 2; Fig. 2). This decrease was independent of the given treatment (Supplementary Table 1). Of the 17 hypoxic lesions at baseline, only seven had a HF > 0 during treatment. In the other ten lesions hypoxia as measured by [18F]HX4 PET imaging had disappeared.

Only one non-hypoxic lesion (TBR = 1.37, HF = 0) at baseline, changed its hypoxic status during treatment. However, The TBRmax increased only from 1.37 at baseline to 1.43 during treatment resulting in a small HF and HV during treatment of 0.4% and 0.2 cm³, respectively.

Spatial stability of [18F]HX4 PET uptake

To perform an analysis of the spatial [18F]HX4 uptake, a significant tracer uptake in both [18F]HX4 PET/CT scans was necessary. Only two lesions (both GTVln) had a HV larger than 1 cm³ during treatment (2.9 and 10.1 cm³). These GTVln were selected for the voxel-wise analysis of the [18F]HX4 uptake within the GTV, resulting in a Pearson’s correlation coefficient of 0.63 and 0.85, respectively. The HV during treatment largely overlapped within the HV at baseline (98 and 100%, respectively; Fig. 3).

Blood biomarkers

At baseline (N = 20) we measured an average concentration of 57 ± 26 ng/ml osteopontin, 190 ± 120 pg/ml CAIX, and 85 ± 67 pg/ml VEGF. There was no inter-correlation between the different plasma parameters. During (chemo)radiotherapy (N = 17), a non-significant decrease in CAIX (173 ± 97 pg/ml; P = 0.45) and VEGF (75 ± 67 pg/ml; P = 0.74) was observed, whereas the increase in osteopontin was significant (65 ± 31 pg/ml; P = 0.04; Supplementary Fig. 2).

Relationship blood biomarkers and [18F]HX4 PET

At baseline none of the blood biomarkers (CAIX, VEGF, and osteopontin) showed a correlation with any of the [18F]HX4 PET image parameters. Also, no correlation between the blood biomarkers and the tumor volume was observed. During treatment, only the osteopontin concentration was
weakly correlated with the SUV\textsubscript{mean} on the $[^{18}\text{F}]$HX4 PET ($R_s = 0.52$, $P = 0.03$; Supplementary Fig. 2).

**Discussion**

In this study we evaluated tumour hypoxia with $[^{18}\text{F}]$HX4 PET in patients with HNSCC before the start of (chemo)radiotherapy and during treatment, with the aim to monitor treatment response and evaluate the spatial variability of the $[^{18}\text{F}]$HX4 uptake. In addition, the concentration of blood hypoxia markers (osteopontin, CAIX, and VEGF) was evaluated at baseline and during treatment. Last, the interdependence between hypoxia PET imaging and hypoxia-related blood biomarkers was investigated.

Before the start of (chemo)radiotherapy, we observed tumour hypoxia in the majority of primary HNSCC and metastatic lymph nodes. However, in most of these lesions, hypoxia disappeared during the course of treatment, regardless of the chosen treatment; radiotherapy alone or in combination with cisplatin or cetuximab. The decrease of hypoxia during treatment has been described in several studies [3, 19–21]. Lee et al. [19] showed with $[^{18}\text{F}]$FMISO PET imaging a decrease in detectable tumour hypoxia from 90 % (18/20 patients) at baseline to 11 % (2/18) after 4 weeks of chemoradiotherapy. In addition, Servagi-Vernat et al. [20] observed a decrease of the $[^{18}\text{F}]$FAZA PET uptake (SUV\textsubscript{max} and HF) in all patients during chemoradiotherapy, which was recently confirmed by Bollineni et al. [21]. From our current results and the previous literature, we can conclude that in patients with HNSCC, hypoxia decreases during treatment, indicating tumour reoxygenation. Nevertheless, also a decrease in cell number, changes in vasculature, or perfusion could contribute to the altered hypoxia PET uptake.

Additionally, our results show that the patients with a high uptake at baseline have the highest chance of persistent hypoxia during treatment. These patients may benefit most from anti-hypoxia therapy during the entire course of treatment. For the other cases, the addition of anti-hypoxia therapy will probably have the largest therapeutic effect when given prior to, or during the first weeks of treatment. Since after this period, the

| Parameter                  | Baseline | During treatment | Difference [%] | Significance ($P$-value) |
|----------------------------|----------|------------------|----------------|--------------------------|
| SUV\textsubscript{mean}    | 0.9 ± 0.2| 0.8 ± 0.2        | −13 ± 19       | 0.02                     |
|                           | (0.7–1.3)| (0.5–1.2)        |                |                          |
| SUV\textsubscript{max}     | 1.5 ± 0.4| 1.1 ± 0.3        | −25 ± 18       | 0.001                    |
|                           | (0.9–2.1)| (0.7–1.9)        |                |                          |
| TMR\textsubscript{max}     | 1.9 ± 0.4| 1.4 ± 0.2        | −27 ± 11       | <0.001                   |
|                           | (1.4–2.8)| (1.0–2.1)        |                |                          |
| Hypoxic fraction [%]       | 22 ± 20  | 4 ± 10           | −93 ± 15       | <0.001                   |
|                           | (3–71)   | (0–40)           |                |                          |
| Hypoxic volume [cm$^3$]    | 4.6 ± 5.2| 0.8 ± 2.5        | −93 ± 15       | <0.001                   |
|                           | (0.1–18.0)| (0.0–10.1)      |                |                          |

Shown are the baseline hypoxic lesions (GTV\textsubscript{prim} and GTV\textsubscript{ln}), with an $[^{18}\text{F}]$HX4 PET/CT scan at baseline and during treatment (total lesions $N = 17$). The provided significance is based on the Wilcoxon signed rank test.

![Fig. 2](image-url) $[^{18}\text{F}]$HX4 PET/CT scan of a patient with a T3N2bMx squamous cell carcinoma of the hypopharynx treated with cisplatin chemo-radiation. **a**: Scan with hypoxic primary tumour at baseline, **b**: decreased level of hypoxia during treatment and **c**: Calculated hypoxic fraction (HF) of all primary tumours and lymph nodes before and during treatment, significant decrease ($p < 0.001$)
amount of tumour hypoxia is low. [18F]HX4 PET imaging has already shown its potential to monitor the response to the anti-hypoxia treatment with TH-302 [22]. The ability to monitor the response to anti-hypoxia treatment with non-invasive imaging provides the potential to adapt the anti-hypoxia treatment based on the (changing) lesion characteristics.

Another frequently discussed method to target resistant tumour volumes is by giving a radiation boost. Previous studies have shown that it is technically feasible to provide a radiotherapy boost to hypoxic or metabolically active tumour subvolumes, defined on PET [4, 23–25]. For this purpose, information on the spatial repeatability of the hypoxia PET uptake and its stability during treatment is essential. In our current data-set only two lesions showed a significant amount of tumour hypoxia during treatment, with a spatially stable localization in comparison to the baseline scan. Where Bittner et al. [26] reported a geographically stable localization of the [18F]FMISO PET uptake during chemoradiotherapy, Nehmeh et al. [27], Lin et al. [27], and Servagi-Vernat et al. [20] reported changes in the distribution of hypoxia during treatment, and, therefore, adaptive radiotherapy based on serial hypoxia PET imaging was recommended.

Serial hypoxia PET imaging during treatment may provide additional information for response prediction. In a preclinical setting, micro-environmental parameters (hypoxia, perfusion) during treatment had a better potential to predict outcome after radiotherapy [28]. This finding was confirmed in a clinical study by Zips et al. [3] in 25 patients with HNSCC. The authors found a significant correlation between [18F]FMISO-PET imaging before and during chemoradiotherapy and local progression free survival, and tumour hypoxia during treatment was of higher prognostic relevance. In our study, accrual is ongoing and the assessment of hypoxia in relationship to outcome will be performed as data have matured.

We hypothesized that blood biomarkers could also be used to monitor treatment response, because previous studies have showed that blood biomarkers have the potential to predict response to treatment [29]. For example, a high concentration of plasma osteopontin was related to a higher amount of locoregional tumour failure in patients with HNSCC [14]. The blood biomarkers CAIX and VEGF, showed no significant changes during treatment and the osteopontin concentration was increased, while hypoxia PET imaging showed a clear reduction of the uptake in all patients. These results might be explained by the patient cohort. When comparing the plasma osteopontin levels of the patients in our current trial to the levels reported in the large randomized trial from Overgaard et al. [14], we observed that all our patients should be assigned to the low or intermediate concentrations of plasma osteopontin. Also, in comparison to a study in 295 patients with advanced rectal cancer, our observed levels of osteopontin and CAIX were lower than their reported average values [29]. In addition, plasma osteopontin is not only influenced by hypoxia, it is also known to play a role in the immune regulation and stress response [30]. An elevated level of osteopontin was for example observed in patients with systemic inflammatory response syndrome or sepsis [31]. The given anti-cancer treatment might have induced an immune/stress response causing an elevated level of osteopontin. The observed concentration of plasma CAIX (190 ± 120 pg/ml) was higher than documented for 209 patients with NSCLC (mean: 45 pg/ml) or 58 healthy individuals (mean: 2.5 pg/mL) [15]. The concentration of plasma VEGF (85 ± 67 pg/ml) was similar to that observed in patients with NSCLC [32] and higher than reported in 50 healthy women (median: 37 pg/mL [33]). Nevertheless, in the current population the blood biomarkers osteopontin, CAIX, and VEGF were not suitable to measure a hypoxia-related treatment response, which was measurable using [18F]HX4-PET.

The correlation between the blood hypoxia markers and the [18F]HX4 PET uptake was absent to weakly present. This was
in agreement with the results previously published by several groups comparing hypoxia PET imaging to tissue or blood markers. Vercellino et al. [34] observed no correlation between the uptake of the hypoxia tracer \([^{18}F]\)FETNIM and the plasma osteopontin concentration in 16 patients with cervical carcinoma. In addition, Gronroos et al. [35] found no correlation between hypoxia PET imaging using FETNIM and several tissue biomarkers in 15 patients with HNSCC. While in patients with newly diagnosed glioma, the preoperative \([^{18}F]\)FMISO PET uptake was significantly, but weakly, correlated to the expression of VEGF in the tumour [36]. Although the current patient population is small, the results suggest that the tested blood biomarkers are not able to replace hypoxia PET imaging, or to pre-select patients for hypoxia PET imaging.

To conclude, hypoxia PET imaging with \([^{18}F]\)HX4 is able to detect tumour hypoxia in patients with HNSCC; in addition, it can monitor a decrease of tumour hypoxia during treatment. In patients with persistent tumour hypoxia, a stable localization of the hypoxic volume was observed. This provides potential for radiotherapy dose escalation to the hypoxic volumes. The blood parameters osteopontin, CAIX, and VEGF were not able to detect a decrease in hypoxia during treatment. In addition, there was no correlation between the blood plasma parameters CAIX and VEGF and hypoxia PET imaging, while only a weak correlation was observed between \([^{18}F]\)HX4 PET imaging and the osteopontin concentration during treatment. Based on the current data, we conclude that hypoxia PET imaging is the superior method to evaluate tumour hypoxia before and during treatment and cannot be replaced with the evaluated blood biomarkers.

Acknowledgments The authors like to thank the patients who agreed to participate and the PET-CT group, data-management (Anita Botterweck) and trial-poli (Claudia Offermann and John Paulissen) of Maastricht University Clinic, for their contribution to the data acquisition.

Compliance with ethical standards Funding Authors acknowledge financial support from the QuIC-ConCePT project, which is partly funded by EFPIA companies and the Innovative Medicine Initiative Joint Undertaking (IMI JU) under Grant Agreement No. 115151. Authors also acknowledge financial support from EU 7th framework program (EURECA, ARTFORCE - n° 257144, REQUITE - n° 601826), Kankeronderzoekfonds Limburg from the Health Foundation Limburg and the Dutch Cancer Society (KWF MAC 2011–4970).

Conflict of interest No actual or potential conflicts of interest exist.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethical Review Committee of Maastricht University Medical Centre.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Nordmark M, Bentzen SM, Radat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2005;77:18–24.
2. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9:674–87.
3. Zips D, Zophel K, Abolmaali N, et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2012;105:21–8.
4. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with \([^{18}F]\)FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2011;101:369–75.
5. van Elsmt W, Ollers M, Dingemans AM, Lambin P, De Ruyscher D. Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J Nucl Med Off Publ Soc Nucl Med. 2012;53:1514–20.
6. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck—a systematic review and meta-analysis. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2011;100:22–32.
7. Kaanders JH, Wijffels KI, Marres HA, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 2002;62:7066–74.
8. Janssens GO, Rademakers SE, Terhaard CH, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:1777–83.
9. Dubois LJ, Lieuws NG, Janssen MH, et al. Preclinical evaluation and validation of \([^{18}F]\)HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A. 2011;108:14620–5.
10. Peeters SG, Zegers CM, Lieuws NG, et al. A comparative study of the hypoxia PET tracers \([^{18}F]\)HX4, \([^{18}F]\)FAZA, and \([^{18}F]\)FMISO in a preclinical tumor model. Int J Radiat Oncol Biol Phys. 2015;91:351–9.
11. Zegers CM, van Elsmt W, Reymen B, et al. In vivo quantification of hypoxic and metabolic status of NSCLC tumors using \([^{18}F]\)HX4 and \([^{18}F]\)FDG-PET/CT imaging. Clin Cancer Res Off J Am Soc Clin Oncol. 2014;20:6389–97.
12. Zegers CM, van Elsmt W, Wiertz R, et al. Hypoxia imaging with \([^{18}F]\)HX4 PET in NSCLC patients: defining optimal imaging parameters. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013;109:58–64.
13. Nordmark M, Eriksen JG, Gebski V, Alsnier J, Horsman MR, Overgaard J. Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2007;83:389–97.
14. Overgaard J, Eriksen JG, Nordmark M, Alsnier J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitizer.
nismorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005;6:757–64.

15. Ilie M, Mazure NM, Hofman V, et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer. 2010;102:1627–35.

16. van Loon J, Janssen MH, Ollers M, et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging. 2010;37:1663–8.

17. Doss M, Zhang JJ, Belanger MJ, et al. Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun. 2010;31:1016–24.

18. Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y. (1)(8)F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with (1)(8)F-FMISO. Nucl Med Commun. 2012;33:1096–102.

19. Lee N, Nehmeh S, Schoder H, et al. Prospective trial incorporating pre-/mid-treatment [18F]-misomidoazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;75:101–8.

20. Servagi-Vernat S, Differding S, Hanin FX, et al. A prospective clinical study of (1)(8)F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1544–52.

21. Bollnieri VR, Koole MJ, Pruim J, et al. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014;113:198–203.

22. Peeters SG, Zegers CM, Biemans R, et al. TH-302 in combination with radiotherapy enhances the therapeutic outcome and is associated with pretreatment [18F]HX4 hypoxia PET imaging. Clin Cancer Res Off J Am Assoc Cancer Res. 2015.

23. Servagi-Vernat S, Differding S, Sterpin E, et al. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: A planning study. Acta Oncol. 2015;1–9.

24. Choi W, Lee SW, Park SH, et al. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2010;97:176–82.

25. Berwouts D, Otteau LA, Duprez F, et al. Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013;107:310–6.

26. Bittner MI, Wiedenmann N, Bucher S, et al. Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013;108:511–6.

27. Nehmeh SA, Lee NY, Schroder H, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235–42.

28. Yaromina A, Kroeber T, Mezner A, et al. Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys. 2011;80:1205–13.

29. Buijsen J, van Stiphout RG, Menheere PP, Lammering G, Lambin P. Blood biomarkers are helpful in the prediction of response to chemoradiation in rectal cancer: a prospective, hypothesis driven study on patients with locally advanced rectal cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014;111:237–42.

30. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19:333–45.

31. Vaschetto R, Nicola S, Olivieri C, et al. Serum levels of osteopontin are increased in SIRS and sepsis. Intensive Care Med. 2008;34:2176–84.

32. Ostheimer C, Bache M, Gottler A, Kotzsch M, Vordermark D. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor. Strahlenther Onkol Organ Dtsch Rontgengesellschaft. 2014;190:276–82.

33. Lawicki S, Zajkowska M, Glazewska EK, Bedkowska GE, Sznitkowski M. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer. Oncol Targets Ther. 2016;9:911–9.

34. Vercellino L, Groheux D, Thoury A, et al. Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET/CT. Clin Nucl Med. 2012;37:1065–8.

35. Gronroos TJ, Lehtio K, Soderstrom KO, et al. Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET. BMC Cancer. 2014;14:876.

36. Kawai N, Lin W, Cao WD, et al. Correlation between (1)(8)F-fluoromisonidazole PET and expression of HIF-1alpha and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging. 2014;41:1870–8.